
Result date: 14th February, 2023
Recommendation: Buy
Target price: Rs 5,150
Apollo Hospitals Enterprise could post revenue growth of 20% over the year-ago quarter and 3% sequentially. Store addition and higher sales from existing stores could drive strong growth in pharmacy revenue.
EBITDA margin though could decline both over the year-ago quarter and sequentially during the quarter. Analysts at IIFL Securities expect Apollo’s growth momentum to sustain across all verticals, thereby leading to 17% EBITDA CAGR for the company over FY22-25.
Profit After Tax (PAT) could decline 2% over the year-ago quarter, but grow 10% sequentially.
Important management insights to watch out for:
December 2022 estimates | YoY change | QoQ change | |
Revenue (Rs mn) | 43,817 | 20% | 3% |
EBITDA (Rs mn) | 5,674 | (3)% | 0% |
EBITDA margin | 12.9% | (318) bps | (35) bps |
Profit After Tax (Rs mn) | 2,237 | (2)% | 10% |
Source: IIFL Research
Invest wise with Expert advice
Get better recommendations Make better investments.
Get better recommendations Make better investments.
By continuing, I accept the Terms & Conditions and agree to receive communication on Whatsapp
The US Federal committee's meeting will conclude on March 16, 2022.
No Record Found